| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2004;35:616.)
© 2004 American Heart Association, Inc.
Original Contributions |
From the Department of Neurology, University Hospital Charité, Berlin (S.W., B.G., G.J.J., P.B., B.M., A.B., N.A., A.V.); Department of Neurology, Heinrich-Heine University, Düsseldorf (V.J., M.S.); Departments of Neurology (R.K., J.R.) and Neuroradiology (T.K.), University of Hamburg, Eppendorf; Departments of Neuroradiology (J.B.F.) and Neurology (P.D.S.), Ruprecht-Karls University, Heidelberg; Institute of Medical Biometrics, Humboldt University, Berlin (K.D.W.); and Medical Faculty, Albert-Ludwigs University, Freiburg (M.W.), Germany.
Correspondence to Susanne Wegener, MD, Department of Neurology, University Hospital Charité, Schumannstrasse 20/21, 10117 Berlin, Germany. E-mail susanne.wegener{at}charite.de
| Abstract |
|---|
|
|
|---|
Methods Sixty-five patients with first-ever ischemic territorial stroke received diffusion- and perfusion-weighted MRI within 12 hours of symptom onset. Epidemiological and clinical data, lesion volumes in T2, apparent diffusion coefficient (ADC) maps and perfusion maps, and cerebral blood flow and cerebral blood volume values were compared between patients with and without a prodromal TIA.
Results Despite similar size and severity of the perfusion deficit, initial diffusion lesions tended to be smaller and final infarct volumes were significantly reduced (final T2: 9.1 [interquartile range, 19.7] versus 36.5 [91.2] mL; P=0.014) in patients with a history of TIA (n=16). This was associated with milder clinical deficits.
Conclusions The beneficial effect of TIAs on lesion size in ADC and T2 suggests the existence of endogenous neuroprotection in the human brain.
Key Words: ischemic attack, transient ischemic preconditioning magnetic resonance imaging neuroprotection stroke
| Introduction |
|---|
|
|
|---|
| Subjects and Methods |
|---|
|
|
|---|
MRI Acquisition and Analysis
MRI was performed on 1.5-T clinical scanners at each study center. Typical sequence parameters of the joint protocol are described elsewhere6,9,10 and in the Appendix. PWI and DWI data were postprocessed with routines developed by Peter Brunecker and Christian Kerskens (Berlin) using IDL 5.0 (Research Systems Inc). Maps of the apparent diffusion coefficient (ADC), mean transit time (MTT), CBF, and CBV were generated from DWI and PWI data, respectively. For CBF and CBV, an arterial input function was calculated following the approach suggested by Ostergaard et al.1113 Lesion volumetry was performed by 2 independent observers blinded to clinical data using National Institutes of Health Image software. Contralateral mirror regions of interest were manually generated as control, and a threshold was set for the definition of the ischemic lesion on the basis of the mean signal intensity of the control region of interest. For analysis of CBF and CBV, masks from the perfusion deficit on MTT maps generated with a planimetric method13 were transferred to the corresponding and mirrored CBF and CBV images with the use of the software package MRIcro,14 thus yielding the matching area of the contralateral hemisphere.15 Recanalization was assessed from day 1 MRI on the basis of MR angiography and PWI studies according to the modified Thrombolysis in Myocardial Infarction (TIMI) criteria.16 Vessel occlusion types were determined from MR angiography as follows: 0=no vessel occlusion, 1=internal cerebral artery occlusion at origin, 2=carotid-T occlusion, 3=proximal middle cerebral artery (MCA) trunk occlusion, 4=distal MCA trunk occlusion, and 5=M2 occlusion.16
Statistical Analysis
Statistical analyses were performed as nonparametric because of small (and different) samples sizes and nonnormal distributions. Results are expressed as medians and interquartile ranges (IQRs). Differences between groups were investigated with the Mann-Whitney test (continuous and categorical data) or Fishers exact test (frequencies). Differences in infarct volumes and CBV and CBF values between the 3 groups (no TIA, TIA
4 weeks, TIA >4 weeks) were analyzed with the Kruskal-Wallis exact test and Mann-Whitney test in a closed testing procedure, securing the multiple level
(in this test procedure the probability of a false-positive decision is not larger than
, regarding all group comparisons). Recanalization and occlusion types were tested with Fishers exact test. Probability values are always given as 2-sided and exact. The multiple regression analysis was accomplished with feature selection in a stepdown procedure and without feature selection. Significance was assessed at the P<0.05 level. Statistical analyses were performed with the use of SPSS for Windows (release 11.0.1, SPSS Inc, 19982001) and StatXact5 (CYTEL Software Corp, 2001).
| Results |
|---|
|
|
|---|
/>4 weeks) because clinically observed protection had been shown to wane within this time period.1 Four remote TIAs (in a different vascular territory than subsequent stroke, which, according to experimental studies,17 are expected to provide ischemic protection as well) were included in the analysis, 2 of these
4 weeks and 2 >4 weeks from stroke. Baseline characteristics of our stroke patient population, presumed stroke etiology, sex, risk factors, thrombolysis, and prestroke medication with acetylsalicylic acid or phenprocoumon (Table 1) resembled previously published cohorts,18 with the exception of a higher prevalence of smokers in the TIA group. Thrombolytic treatment was administered in 40.8% (n=20) of patients without TIA and in 31.3% (n=5) of patients with prodromal TIA at a time interval of 157.5 (IQR, 80.0) minutes and 152.5 (IQR, 83.8) minutes after symptom onset, respectively (P=0.57). Time of first MRI assessment was 4.5 (IQR, 4.5) hours in the no-TIA group and 4.9 (IQR, 4.5) hours in the TIA group (P=0.54). Stroke symptoms and functional disability were significantly less severe in patients with prodromal TIA at the acute stage (<12 hours) as well as on discharge (Table 1).
|
For lesion volumetry, we calculated ADC and MTT maps from DWI and PWI data, respectively. We further analyzed the area of restricted perfusion delineated on the MTT maps for changes in CBF and CBV after determination of the arterial input function11,12 (Table 2 and Figure).
|
|
The final infarct volume was significantly smaller in stroke patients with prodromal TIA than in those with first-ever brain ischemia (final T2: 9.1 [IQR, 19.7] versus 36.5 [IQR, 91.2] mL; P=0.014), which was even more pronounced when only TIAs
4 weeks were analyzed (5.6 [IQR, 8.6] mL; P=0.002). Initial ADC lesion volume was smaller and closely resembled final infarct size (12.7 [IQR, 20.4] versus 20.7 [IQR, 40.9] mL), but the Kruskal-Wallis test for the 3 groups did not show statistical significance (P=0.081). However, with a maximal difference of 23.4 versus 8.1, we calculated a power of only 24% (n=16). All groups had approximately the same size of perfusion restriction. Median CBF and CBV values were similar in both groups.13
To evaluate the degree of recanalization and occlusion types, we examined MR angiography and MTT maps of the initial and first follow-up examinations (Table 3). We compared no or minimal recanalization (TIMI 0 and 1) with incomplete and complete recanalization (TIMI 2 and 3) on day 2. Of the 54 patients with sufficient data, there was no significant difference between patients without or with prodromal TIA (P=0.34). Occlusion types were grouped into proximal (categories 1, 2, and 3) and distal (4 and 5) occlusions16 and into carotid (1 and 2) versus other (3, 4, and 5) occlusion types because of the a priori knowledge18 that carotid stenosis is more frequently associated with TIA compared with other subtypes of stroke. While the proportion of proximal and distal occlusion types was similar in both groups (P=1), we found more type 1 occlusions (proximal carotid stenosis) in the prodromal TIA group (P=0.022).
|
To determine whether this group difference or other factors were determinants of final infarct size, we conducted a multiple linear regression analysis in a stepdown procedure as well as without feature selection, including infarct etiology, age, thrombolysis, smoking, hypertension, diabetes, prodromal TIA, recanalization, and occlusion type. Separately, we tested TIA
4 weeks and >4 weeks to account for time of TIA (Table 4; results from feature selection for each model are marked with an asterisk). Carotid occlusion (types 1 and 2) was a significant factor in all models related to large final infarct size. Most importantly, prodromal TIA was a significant factor with a negative relationship to final infarct size, which was also evident without feature selection (P=0.039; 95% CI, -106.1 to -2.9). None of the other factors considered were significant. TIA >4 weeks was not a significant variable, while TIA
4 weeks showed significance (P=0.007) only after feature selection. Although the small number of patients in these TIA subgroups may account for the latter results, on the basis of these data, we cannot identify time of TIA as an independent determining variable of final T2.
|
| Discussion |
|---|
|
|
|---|
In this study we extended the initial clinical observations regarding reduced symptom severity in stroke after prodromal TIA.1,2 The fact that sizes of the perfusion lesion as well as CBF and CBV values were not different between patients with and without prodromal TIAs indicates that both patient groups were subjected to the same extent and severity of flow restriction and microvascular capacity disruption. Nevertheless, infarcts in patients with prodromal TIA were smaller. To our knowledge, this is the first study to suggest that protection by a prodromal TIA is not explained by changes in blood flow, as would be expected from collateral recruitment or enhanced vascularization, but rather by intrinsic neuroprotective mechanisms.
A drawback of this study is the small sample size of the TIA group, which was not overcome with the multicenter approach. Differences in recanalization rate in favor of the TIA group and the higher number of carotid stenoses make interpretation of our data less straightforward, even though these potential confounders were adjusted for in the multiple regression analysis. We believe that the trend toward a higher recanalization rate in the TIA group is unlikely to be the cause for reduced final infarct volumes in this study because at the acute assessment, when vascular occlusion was still present, initial diffusion was already smaller. The higher percentage of smokers and lower incidence of a cardioembolic infarct etiology in the TIA group may also influence outcome measures, even though it does not explain the temporary nature of protection. Still, these findings suggest interesting alternative explanations, such as differences in thrombolytic activity between patient groups, possibly as a result of less tissue destruction or different thrombus characteristics. Acute DWI lesion sizes as well as final infarct volumes were smaller in patients with a prodromal TIA
4 weeks from subsequent stroke compared with TIAs >4 weeks in univariate analysis, but time of TIA was not a significant variable of T2 lesion size in regression analysis without feature selection. Therefore, the differences in infarct sizes present in the 2 groups may be due to factors other than time of TIA.
In conclusion, we show that patients with prodromal TIAs display different patterns of diffusion and perfusion deficit in a subsequent stroke. Despite a similar perfusion lesion, their final infarcts are smaller. The only parameter predictive of small final infarct size in a multiple regression analysis was prodromal TIA. Although a TIA is an alarming sign for patients and clinicians indicating an underlying vascular disorder, the potential clinical relevance of our findings lies in its possible application in the clinical setting: many transducers of the preconditioning signal are known from in vitro models. Further delineation and exploration of naturally occurring ischemic tolerance may be a new perspective in future neuroprotection and acute stroke therapy.
| Appendix |
|---|
|
|
|---|
| Acknowledgments |
|---|
Received June 15, 2003; revision received October 27, 2003; accepted November 11, 2003.
| References |
|---|
|
|
|---|
2. Weih M, Kallenberg K, Bergk A, Dirnagl U, Harms L, Wernecke KD, Einhäupl KM. Attenuated stroke severity after prodromal TIA: a role for ischemic tolerance in the brain? Stroke. 1999; 30: 18511854.
3. Kirino T. Ischemic tolerance. J Cereb Blood Flow Metab. 2002; 22: 12831296.[CrossRef][Medline] [Order article via Infotrieve]
4. Chen J, Graham SH, Zhu RL, Simon RP. Stress proteins and tolerance to focal cerebral ischaemia. J Cereb Blood Flow Metab. 1996; 16: 566577.[CrossRef][Medline] [Order article via Infotrieve]
5. Beaulieu C, de Crespigny A, Tong DC, Moseley ME, Albers GW, Marks MP. Longitudinal magnetic resonance imaging study of perfusion and diffusion in stroke: evolution of lesion volume and correlation with clinical outcome. Ann Neurol. 1999; 46: 568578.[CrossRef][Medline] [Order article via Infotrieve]
6. Schellinger PD, Fiebach JB, Jansen O, Ringleb PA, Mohr A, Steiner T, Heiland S, Schwab S, Pohlers O, Ryssel H, et al. Stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia. Ann Neurol. 2001; 49: 460469.[CrossRef][Medline] [Order article via Infotrieve]
7. Wardlaw JM, Dennis MS, Warlow CP, Sandercock PA. Imaging appearance of the symptomatic perforating artery in patients with lacunar infarction: occlusion or other vascular pathology? Ann Neurol. 2001; 50: 208215.[CrossRef][Medline] [Order article via Infotrieve]
8. Adams HP, Bendixen BH, Kapelle LJ, Biller J, Love BB, Gordon DL, Marsh EE, and the TOAST Investigators. Classification of subtype of acute ischemic stroke: definitions to use in a multicenter clinical trial. Stroke. 1993; 24: 3541.
9. Fiehler J, Foth M, Kucinski T, Knab R, von Bezold M, Weiller C, Zeumer H, Röther J. Severe ADC decreases do not predict irreversible tissue damage in humans. Stroke. 2002; 33: 7986.
10. Doege CA, Kerskens CM, Romero BI, Brunecker P, Junge-Hülsing J, Müller B, Villringer A. MRI of small human stroke shows reversible diffusion changes in subcortical gray matter. Neuroreport. 2000; 11: 20212024.[Medline] [Order article via Infotrieve]
11. Ostergaard L, Weisskopf RM, Chesler DA, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages, part I: mathematical approach and statistical analysis. Magn Reson Med. 1996; 36: 715725.[Medline] [Order article via Infotrieve]
12. Ostergaard L, Sorensen AG, Kwong KK, Weisskopf RM, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages, part II: experimental comparison and preliminary results. Magn Reson Med. 1996; 36: 726736.[Medline] [Order article via Infotrieve]
13. Sorensen AG, Copen WA, Ostergaard L, Buonanno FS, Gonzalez RG, Rordorf G, Rosen BR, Schwamm LH, Weisskopf RM, Koroshetz WJ. Hyperacute stroke: simultaneous measurement of relative cerebral blood volume, relative cerebral blood flow, and mean transit time. Radiology. 1999; 210: 519527.
14. Rorden C, Brett M. Stereotaxic display of brain lesions. Behav Neurol. 2000; 12: 191200.[Medline] [Order article via Infotrieve]
15. Rohl L, Ostergaard L, Simonsen CZ, Vestergaards-Poulsen P, Andersen G, Sakoh M, Le Bihan D, Gyldensted C. Viability thresholds of ischemic penumbra of hyperacute stroke defined by perfusion-weighted MRI and apparent diffusion coefficient. Stroke. 2001; 32: 11401146.
16. Rother J, Schellinger PD, Gass A, Siebler M, Villringer A, Fiebach JB, Fiehler J, Jansen O, Kucinski T, Schoder V, et al, for the Kompetenznetzwerk Schlaganfall Study Group. Effect of intravenous thrombolysis on MRI parameters and functional outcome in acute stroke <6 hours. Stroke. 2002; 33: 24382445.
17. Kharbanda RK, Mortensen UM, White P, Kristiansen SB, Schmidt MR, Hoschitzky JA, Vogel M, Sorensen K, Redington AN, MacAllister R. Transient limb ischemia induces remote ischemic preconditioning in vivo. Circulation. 2002; 106: 28812883.
18. Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, Glahn J, Brandt T, Hacke W, Diener HC. Risk factors, outcome, and treatment in subtypes of ischemic stroke: the German Stroke Data Bank. Stroke. 2001; 32: 25592566.
19. Fisher M, Ratan R. New perspective on developing acute stroke therapy. Ann Neurol. 2003; 53: 1020.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
R. Meller The Role of the Ubiquitin Proteasome System in Ischemia and Ischemic Tolerance Neuroscientist, June 1, 2009; 15(3): 243 - 260. [Abstract] [PDF] |
||||
![]() |
M. Yenari, K. Kitagawa, P. Lyden, and M. Perez-Pinzon Metabolic Downregulation: A Key to Successful Neuroprotection? Stroke, October 1, 2008; 39(10): 2910 - 2917. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Ovbiagele, S. Starkman, P. Teal, P. Lyden, M. Kaste, S. M. Davis, W. Hacke, M. Fierus, J. L. Saver, and on behalf of the VISTA Investigators Serum Calcium as Prognosticator in Ischemic Stroke Stroke, August 1, 2008; 39(8): 2231 - 2236. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhang, Z.-J. Yang, J. A. Klaus, R. C. Koehler, and J. Huang Delayed Tolerance With Repetitive Transient Focal Ischemic Preconditioning in the Mouse Stroke, March 1, 2008; 39(3): 967 - 974. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Deplanque, I. Masse, C. Lefebvre, C. Libersa, D. Leys, and R. Bordet Prior TIA, lipid-lowering drug use, and physical activity decrease ischemic stroke severity Neurology, October 24, 2006; 67(8): 1403 - 1410. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Sanossian, J. L. Saver, V. Rajajee, S. L. Selco, D. Kim, T. Razinia, and B. Ovbiagele Premorbid antiplatelet use and ischemic stroke outcomes Neurology, February 14, 2006; 66(3): 319 - 323. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Fiehler, K. Knudsen, G. Thomalla, E. Goebell, M. Rosenkranz, C. Weiller, J. Rother, H. Zeumer, and T. Kucinski Vascular Occlusion Sites Determine Differences in Lesion Growth from Early Apparent Diffusion Coefficient Lesion to Final Infarct AJNR Am. J. Neuroradiol., May 1, 2005; 26(5): 1056 - 1061. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Pasupathy and S. Homer-Vanniasinkam Surgical Implications of Ischemic Preconditioning Arch Surg, April 1, 2005; 140(4): 405 - 409. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Johnston Ischemic Preconditioning From Transient Ischemic Attacks?: Data From the Northern California TIA Study Stroke, November 1, 2004; 35(11_suppl_1): 2680 - 2682. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. P. Stenzel-Poore, S. L. Stevens, and R. P. Simon Genomics of Preconditioning Stroke, November 1, 2004; 35(11_suppl_1): 2683 - 2686. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. R. Ratan, A. Siddiq, L. Aminova, P. S. Lange, B. Langley, I. Ayoub, J. Gensert, and J. Chavez Translation of Ischemic Preconditioning to the Patient: Prolyl Hydroxylase Inhibition and Hypoxia Inducible Factor-1 as Novel Targets for Stroke Therapy Stroke, November 1, 2004; 35(11_suppl_1): 2687 - 2689. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |